BUSINESS

Trump Announces New Drug-Pricing Deals With Nine Additional Pharma Firms

PUBLISHED Aug 31, 2026, 7:06 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 31

Left 6%

Center 94%

Sources: 31

President Donald Trump announced new agreements with nine midsize pharmaceutical firms to lower prescription costs under his international drug pricing initiative. The latest additions including Alcon, Astellas Pharma, Teva Pharmaceuticals, and UCB bring total participating companies to twenty six, covering roughly eighty nine percent of the domestic branded pharmaceutical market. Under the accords, participating manufacturers will provide state Medicaid programs access to international reference pricing and offer steep direct consumer discounts through the TrumpRx platform. Administration officials project the cumulative agreements will generate over six hundred billion dollars in savings for American consumers over the coming decade. Additionally, the newly signed manufacturers committed nearly twenty billion dollars toward expanding domestic manufacturing and research infrastructure. The policy aims to counter foreign price controls that officials argue shift the financial burden of global drug innovation onto American patients. While praised by supporters for reducing healthcare expenses, critics note that details remain confidential.

By Emily Rhodes | JQJO News

Timeline of Events

On July 31, 2025, President Trump demanded lower drug prices.
On December 19, 2025, administration officials announced initial major pharma agreements.
On February 5, 2026, the federal TrumpRx portal officially launched.
On April 2, 2026, the administration introduced pharmaceutical import tariffs.
On April 23, 2026, Regeneron signed a drug pricing accord.
On August 31, 2026, President Trump announced nine new agreements.
On September 1, 2026, the White House published official facts.
In late 2026, analysts expect continued debate over pricing impacts.
Throughout 2027, participating companies will expand domestic manufacturing facility investments.
By 2036, cumulative healthcare program savings should reach projected targets.

News Intelligence

Immediate US impact: States gain Medicaid price discounts and consumers see direct savings.
Possible long-term US impact: Domestic pharmaceutical manufacturing expands while overall prescription drug costs decrease.
Most affected groups: Medicaid beneficiaries, midsize drug manufacturers, patients, and uninsured American consumers.
Reader Priorities: Verify official White House documents and independent healthcare market analyses.

Media Bias

Articles Published:: 31
Right Leaning:: 0
Left Leaning:: 2
Neutral:: 29

Explain Framing

Left: Critics emphasize voluntary confidentiality and question long term Medicaid savings. Center: Reports emphasize official figures, white house announcements, and market scope. Right: Supporters highlight historic manufacturing investments and lower drug costs.